Saturday, March 3, 2018
South Hall A2 (Convention Center)
Pamela P. Silva, Lais Gomes Japiassú, Patrícia Guerzet Ayres Bastos, Luis Felipe C. Ensina, MD, PhD, Ines Cristina Camelo Nunes, Dirceu Sole, MD PhD FAAAAI, Barbara Martins de Aquino, Chayanne Andrade de Araújo, Alex Eustáquio de Lacerda, Marina Medeiros Caputo
RATIONALE: To compare the clinical characteristics and treatment response in adults and children with Chronic urticaria (CU).

METHODS: Retrospective analysis of medical records of patients treated at a center of excellence in urticaria. Patients under 18 were considered children.

RESULTS: A total of 113 patients with CU (4-76 years of age) were evaluated from April/2016 to June/2017, 31 of whom were children. The symptoms duration was on average 139 weeks longer in adults. In both groups there was a direct relation between disease severity and duration. CU was more prevalent in females. Atopy was more prevalent in children (58%) than in adults (23%) (p <0.05). NSAIDs were associated with CU more frequently in adults (25.6%) than in children (6.5%) (p <0.05). There was no difference in autoimmunity prevalence between adults and children (21,9% and 29% respectively). The disease was under control (UAS7≤6) in 64.5% of children but just in 37.8% of adults (p <0.05). Licensed doses of antihistamines were required for disease control in 19% of children and in 16% of the adults, while higher doses (up to 4 times) could control the symptoms in 35% and 14% respectively. A similar number of patients (10%) needed 3rd line therapy drugs (omalizumab, cyclosporine and montelukast) for symptoms management .

CONCLUSIONS: Pediatric patients have CU for a shorter duration than adults. Atopy could be considered a risk factor for CU in pediatric patients. CU and NSAIDs association is more frequent in adults. Children are better controlled and need less medication than adults.